$CGEM has received 7 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on October 20, 2025. @jacobplieth dominates discussion of Cullinan Oncology with 8 mentions, while @adamfeuerstein contributed 1 mention. The biotech sector represents the primary discussion category for this ticker.

The most recent activity around $CGEM occurred in late May 2026, centered on clinical trial data presented at ASCO26. @jacobplieth posted multiple updates regarding Dizal Zegfrovy data from the WU-Kong28 trial in first-line exon20 NSCLC, noting issues with crossover affecting overall survival benefit. Earlier in May, @adamfeuerstein referenced $CGEM in the context of acquisition discussions involving UCB and Candid.